Introduction: What they say:
A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity against microbial infection.” This study was published, in the 2 March 2015 issue of the Journal “Nature Immunology” [the number one journal in immunological research with an impact factor of 24.973], by Drs. Zusen Fan, Xia and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene
From Research Findings to Therapeutic Opportunity:
This study suggests, for the first time, the dyslipidemia drug Ezetimibe, by decreasing the expression of its target gene, it may : (1) increase the expression of Sox2; (2) increase the ability of Sox2 to recognize bacterial DNA in the cytoplasm; and (3) promote innate immunity against bacterial infection.
Together, pharmacological formulations encompassing “Ezetimibe or its analogs, either alone or in combination with other drugs,“ may be used to (1) enhance innate immunity against bacterial infection; and (2) promote bacterial resistance (figs. 1-2).
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does ezetimibe enhance innate immunity against bacterial infection?
# Research cooperation
For purchase and payment details, you may reach us at email@example.com
Citation: Boominathan, L., Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 14/February/2019, 6.41 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org